Biosimilars Approval to Biogenerics in Clinical Practice

Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a biosimilars. According to current literature, the following points on biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in biosimilars.

  • Biotechnologic drug
  • Monoclonal antibody
  • Fusion protein
  • Biologic drug
  • Anti–tumor necrosis factor

Related Conference of Biosimilars Approval to Biogenerics in Clinical Practice

October 24-25, 2018

13th International Conference on Biopharma and Biotherapeutics

Boston, Massachusetts, USA
November 05-07, 2018

18th Annual Pharma Middle East Congress

Radisson Blu Hotel, Yas Island, Abu Dhabi, UAE
November 14-15, 2018

13th World Congress on Pharmacology and Toxicology

Melbourne, Australia
November 15-16, 2018

9th Global Experts Meeting on Neuropharmacology

Berlin, Germany
January 30-31, 2019

19th World Congress on Advances in Pharmaceutical Sciences

Seoul, South Korea
January 31-February 01, 2019

9th World Congress on Chromatography

Paris | France
February 20-21, 2019

World Congress on Drug Discovery and Drug Design

Singapore
February 22-23, 2019

13th World Drug Delivery Summit

San Francisco, USA
Feb 28-March 01, 2019

International Conference on Bio-Pharmaceuticals

Osaka, Japan
March 25-26, 2019

World Congress on Pharmaceutical Biotechnology & Bioengineering

Orlando, Florida, USA
March 27-28, 2019

5th International Conference on Clinical Pharmacy and
Health Care

San Antonio, Texas, USA
April 04-06, 2019

4th Annual Congress on Nanomedicine and Drug Delivery

Auckland, NewZealand
April 15-16, 2019

12th European Biosimilars Congress

Berlin, Germany
April 17-18, 2019

11th World Congress on Pharmacology & Therapeutics

Montreal, Canada
April 17-18, 2019

Annual Neurochemistry and Neuropharmacology Congress

| Montreal, Canada
April 17-18, 2019

International Conference on Global Analytica

Osaka, Japan

April 22-23, 2019

6th World Congress on Drug Discovery & Toxicology

Abu Dhabi, UAE
May 9-11, 2019

11th World Congress on Neuropharmacology

Prague, Czech Republic
May 20-22, 2019

21st Annual European Pharma Congress

Zurich, Switzerland
April 22-24, 2019

20th Asia-Pacific Pharma Congress

Tokyo, Japan
March 22-23, 2019

5th International Conference on Antibiotics

Orlando, USA
June 17-18, 2019

7 th European Biopharma Congress

Stockholm, Sweden
June 17-18, 2019

14th World Congress on Pharmacology and Drug Safety

Lisbon, Portugal
June 27-29, 2019

18th Annual Congress on Pharmaceutics & Drug Delivery Systems

Amsterdam, Netherlands
July 19-20, 2019

8th International Conference on Clinical Trials

| Atlanta, USA

August 19-20, 2019

24th World Congress on Pharmacology

Vienna, Austria

Biosimilars Approval to Biogenerics in Clinical Practice Conference Speakers

Recommended Sessions

Related Journals

Are you interested in